Navigation Links
The Leukemia & Lymphoma Society Announces Appointment of New President and CEO
Date:4/10/2008

John Walter, with LLS Since 1995, Tapped to Steer the World's Largest

Organization Dedicated to Blood Cancer Research and Patient Services

WHITE PLAINS, N.Y., April 10 /PRNewswire/ -- The Leukemia & Lymphoma Society has appointed John Walter as its president and chief executive officer, with the task of leading the world's largest organization dedicated to funding blood cancer research as it strives to find cures and prolong and enhance the lives of patients with leukemia, lymphoma and myeloma.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080410/NYTH074 )

Walter, who has been with LLS since 1995, most recently as chief operating officer, succeeds Dwayne Howell, Ph.D., who retired in February.

"After conducting a nationwide search, the LLS Board of Directors agreed that John Walter was the best candidate to steer us as we move toward achieving our mission of curing blood cancers and improving the lives of patients and their families," said LLS Chairman David Frantze. "The Leukemia & Lymphoma Society is a $300 million plus organization committed to identifying the best scientists in the world in the field of blood cancer research and providing the funding to help them find cures and better therapies. In John, we have somebody at the helm with the vision and leadership qualities to provide support for our patients in their journey dealing with these devastating diseases."

Walter started his career at LLS as senior vice president of finance and information technology, during which time he enhanced the efficiencies and internal controls of the organization by centralizing all finance and treasury operations in the United States and Canada. He also established LLS's information technology and Web functions.

He served as chief financial officer, and then, as executive vice president, strategic alliances and new business development he desi
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Meadows, Ill. (PRWEB) , ... September 01, 2015 ... ... procedures done by members of the American Society for Dermatologic Surgery, according to ... , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects ...
(Date:9/1/2015)... ... 2015 , ... Negative pressure wound therapy (NPWT) entails the ... exudates, fluid, and infectious materials to prepare the wound for healing and closure. ... canisters, etc.) is projected to expand continuously through 2021. , Rising patient and ...
(Date:9/1/2015)... ... 01, 2015 , ... OncLive® today announced it ... & World Report, to provide breaking news and information about the hospital’s pioneering ... OncLive, which provides oncologists resources and information?they need to deliver the best care ...
(Date:9/1/2015)... ... 01, 2015 , ... PetPace, the provider of an innovative ... activity, today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Practice Management Software packages in the US. Practice Management Software helps veterinarians manage ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit ... version 5.2 of the FirstSpirit Content Management System with new capabilities and enhancements ... version of FirstSpirit, companies will be well on their way to achieving digital ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3
... March 15, 2011Since the first laparoscopic procedure was performed ... Washington University in St. Louis, this breakthrough minimally invasive ... nephrectomy. This remarkable achievement is celebrated with a series ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ...
... are not successfully treated for depression are at higher risk ... to a study in the March 15, 2011 issue of ... as a third of those who experience a stroke develop ... the schools of health and rehabilitation sciences and of medicine ...
... Institutet in Sweden shows, that a specific inflammatory factor ... valve disease aortic stenosis. The results suggest that anti-inflammatory ... stenosis is the most common heart valve disease, which ... the aortic valve. This is typically seen in the ...
... (BCS) results from hepatic venous outflow obstruction,at any ... Few patients respond to,medical treatment (anticoagulation thrombolytic ... restore the hepatic blood flow. Restoring outflow in ... dilatation stenting is the management of choice. ...
... HealthDay Reporter , MONDAY, March 14 (HealthDay News) ... for type 2 diabetes, an older drug -- metformin -- ... analysis of research on diabetes medications. The analysis ... all of them lower blood sugar levels by a similar ...
... home industry is booming in China as a rapid ... a nationwide shift from traditional family care to institutional ... The study, led by Zhanlian Feng, assistant professor ... Journal of the American Geriatrics Society , is the ...
Cached Medicine News:Health News:20th anniversary of first laparoscopic nephrectomy 2Health News:Managing post-stroke depression improves physical functioning 2Health News:Managing post-stroke depression improves physical functioning 3Health News:Inflammation behind heart valve disease 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 3Health News:Nursing home boom in China has little government involvement 2Health News:Nursing home boom in China has little government involvement 3
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: